ArticleMicrobiome2020
Skin microbiota analysis-inspired development of novel anti-infectives.
Article in Microbiome, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- Probiotics and Their Effect on Surgical Wound Healing: A Systematic Review and New Insights into the Role of Nanotechnology.Nutrients · 2021Pooled it
- Effect of combined probiotics and doxycycline therapy on the gut-skin axis in rosacea.mSystems · 2024Trial
- 5-α reductase inhibition by Epilobioum fleischeri extract modulates facial microbiota structure.International journal of cosmetic science · 2022Trial
- Assessment of Protective Role of Different Probiotic Strains against Bacterial and Endotoxin-Induced Sepsis in a Mouse Model.Probiotics and antimicrobial proteins · 2026Article
- The Role of Biotics in Rosacea: A Narrative Review.Cureus · 2026Review
- Immunonutrition: Feeding the gut, skin, and immune system.Asia Pacific allergy · 2026Review
- Staphylococcus capitis strain producing dual bacteriocins, capidermicin and micrococcin P1, shows broad-spectrum antimicrobial activity.Scientific reports · 2026Article
- Article
- An antimicrobial daptide from human skin commensal Staphylococcus hominis protects against skin pathogens.Nature communications · 2025Article
- Identification and Functional Analysis of Novel SNPs in Enterocin Genes of Enterococcus faecium GHB21.Probiotics and antimicrobial proteins · 2025Article
- Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections:Drug delivery · 2025Review
- Draft genome sequences ofMicrobiology resource announcements · 2025Article
- Feeding the Skin Barrier: The Impact of Macro- and Micronutrients on Skin Barrier Function.Clinical and translational allergy · 2025Review
- Review
- Exploring the bioactive landscape: peptides and non-peptides from the human microbiota.NPJ biofilms and microbiomes · 2025Review
- Staphylococcus hominis as a source of antimicrobial peptides: identification of a new peptide with potential antimicrobial properties using in silico approach.Archives of microbiology · 2025Article
- Genomic Analysis of Bacteriocin-Producing Staphylococci: High Prevalence of Lanthipeptides and the Micrococcin P1 Biosynthetic Gene Clusters.Probiotics and antimicrobial proteins · 2025Article
- Article
- Small regulatory RNA RSaX28 promotes virulence by reinforcing the stability of RNAIII in community-associated ST398 clonotypeEmerging microbes & infections · 2024Article
- Phenotypic Variation inAntibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThe alarming spread of antimicrobial resistance requires the development of novel anti-infective drugs. Despite the recent research focus on the human microbiome and its likely value to understand and exploit inter-bacterial inhibitory phenomena as a source for antimicrobial strategies, the human microbiota has barely been investigated for the purpose of drug development.
resultsWe performed a large screen analyzing over 3000 human skin isolates to evaluate bacterial competition within the human skin microbiota as a basis for the development of anti-infective therapeutics. We discovered a Staphylococcus hominis strain with strong and broad activity against Gram-positive pathogens that was mediated by the bacteriocin micrococcin P1 (MP1). In "probiotic" approaches, this strain led to reduced Staphylococcus aureus infection and accelerated closure of S. aureus-infected wounds. Furthermore, we used a nanoparticle strategy to overcome the physico-chemical limitations often encountered with natural substances such as MP1 and demonstrate a significant reduction of S. aureus infection by MP1-loaded nanoparticles.
conclusionsOur study gives examples of how analysis of bacterial interactions in the human microbiota can be explored for the development of novel, effective anti-infective strategies. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.